Literature DB >> 11266513

Inhibition of protein phosphatase PP1 in GH3B6, but not in GH3 cells, activates the MEK/ERK/c-fos pathway and the human prolactin promoter, involving the coactivator CPB/p300.

I Manfroid1, J A Martial, M Muller.   

Abstract

The human (hPRL) PRL gene proximal promoter (-164/+15) is the target for numerous signal transduction pathways involving protein kinases. The inhibitor of Ser/Thr-protein phosphatases okadaic acid (OA) was shown to induce this promoter in rat pituitary GH3B6 through a synergism between increased amounts of the ubiquitous factor AP-1 and the pituitary-specific factor Pit-1. Here we show that this activation results mainly from transcriptional stimulation of the c-fos promoter leading to increased AP-1 activity. We report the surprising absence of the hPRL and c-fos promoter stimulation by OA in GH3 cells, closely related to GH3B6 cells, and we use this discrepancy to dissect the precise mechanism of action. c-fos gene activation involves the mitogen-activated kinase (MAPK)-ternary complex factor (TCF) pathway and can be obtained by expressing active V12ras in both cell lines. We show that OA acts by inhibiting protein phosphatase PP1, thereby protecting MAPK kinase (MEK)1/2 and/or a MEK1/2-kinase from dephosphorylation. PP1 inhibition of MEK activation by V12ras does not occur in GH3 cells, indicating that a distinct, PP1-sensitive phosphorylation site is used in GH3B6 cells to activate the TCF pathway in GH3B6 cells. Finally, we show that the synergistic OA activation of the hPRL promoter by Pit-1 and AP-1 is independent of the Pit-1 transactivation domain and is mediated by the general coactivator (CRE-binding protein)-binding protein (CBP)/p300.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266513     DOI: 10.1210/mend.15.4.0615

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  6 in total

1.  DARPP-32 is required for MAPK/ERK signaling in thyroid cells.

Authors:  Ana Chocarro-Calvo; Miguel A Zaballos; Pilar Santisteban; Custodia García-Jiménez
Journal:  Mol Endocrinol       Date:  2012-02-02

2.  BubR1 deficiency results in enhanced activation of MEK and ERKs upon microtubule stresses.

Authors:  Y L Yang; Q Duan; T B Guo; X X Wang; Q Ruan; G T Xu; J W Zhang; Z Y Lu; M Xu; L Lu; W Dai
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

3.  Quantitative measurement of estrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways.

Authors:  Nataliya N Bulayeva; Bahiru Gametchu; Cheryl S Watson
Journal:  Steroids       Date:  2004-03       Impact factor: 2.668

4.  Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.

Authors:  Kazuyuki Matsushita; Kouichi Kitamura; Bahityar Rahmutulla; Nobuko Tanaka; Takayuki Ishige; Mamoru Satoh; Tyuji Hoshino; Satoru Miyagi; Takeshi Mori; Sakae Itoga; Hideaki Shimada; Takeshi Tomonaga; Minoru Kito; Yaeko Nakajima-Takagi; Shuji Kubo; Chiaki Nakaseko; Masahiko Hatano; Takashi Miki; Masafumi Matsuo; Masaki Fukuyo; Atsushi Kaneda; Atsushi Iwama; Fumio Nomura
Journal:  Oncotarget       Date:  2015-03-10

5.  The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes.

Authors:  Francesca Capone; Eliana Guerriero; Giovanni Colonna; Patrizia Maio; Alessandra Mangia; Raffaele Marfella; Giuseppe Paolisso; Francesco Izzo; Nicoletta Potenza; Luigi Tomeo; Giuseppe Castello; Susan Costantini
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

6.  Interrogating PP1 Activity in the MAPK Pathway with Optimized PP1-Disrupting Peptides.

Authors:  Yansong Wang; Bernhard Hoermann; Karolina Pavic; Malgorzata Trebacz; Pablo Rios; Maja Köhn
Journal:  Chembiochem       Date:  2018-11-26       Impact factor: 3.164

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.